Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses Yoshiya TanakaTsutomu TakeuchiVijay Rajendran Review Open access 05 September 2023 Pages: 1399 - 1415
Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis Blanca Hernández-CruzUta KiltzFabrizio Conti Review Open access 16 September 2023 Pages: 1417 - 1457
Targeting DORIS Remission and LLDAS in SLE: A Review Agner R. Parra SánchezRonald F. van VollenhovenAlessandro Sorrentino Review Open access 05 October 2023 Pages: 1459 - 1477
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Philip J. MeaseAlexis OgdieJoseph F. Merola Original Research Open access 19 August 2023 Pages: 1479 - 1501
Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice Stephanie G. WernerXenofon BaraliakosAxel J. Hueber Original Research Open access 11 September 2023 Pages: 1503 - 1518
A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis Leslie R. HarroldPatrick ZuegerPankaj A. Patel Original Research Open access 20 September 2023 Pages: 1519 - 1533
Association Between Mycophenolate Mofetil Use and Subsequent Infections Among Hospitalized Patients with Systemic Lupus Erythematosus: A Nested Case–Control Study Qingqing GuoXueyi ZhangZiyi Jin Original Research Open access 24 September 2023 Pages: 1535 - 1554
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Alejandro BalsaSiegfried WassenbergPatrick Verschueren Original Research Open access 25 September 2023 Pages: 1555 - 1574
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients Rieke AltenGerd R. BurmesterBruno Fautrel Original Research Open access 27 September 2023 Pages: 1575 - 1595
Analysis of Factors Influencing Whole Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus in China Xuan HuangQing ShuYujie Zhou Original Research Open access 27 September 2023 Pages: 1597 - 1607
Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study Chan-yuan WuQian WangXiao-feng Zeng Original Research Open access 28 September 2023 Pages: 1609 - 1622
Risk of Macrophage Activation Syndrome in Patients with Adult-Onset Still’s Disease Treated with IL-1 and IL-6 Inhibitors: A Meta-analysis and Single-Center Experience Soichiro AdachiKaoru Takase-MinegishiHideaki Nakajima Original Research Open access 04 October 2023 Pages: 1623 - 1636
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study Philip J. MeaseDafna D. GladmanXenofon Baraliakos Original Research Open access 11 October 2023 Pages: 1637 - 1653
Psoriasis and Psoriatic Arthritis Have a Major Impact on Quality of Life and Depressive Symptoms: A Cross-Sectional Study of 300 Patients Natalie FredeSonja HiestandNils Venhoff Original Research Open access 15 October 2023 Pages: 1655 - 1668
A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis Laura C. CappelliGeorge ReedJoel M. Kremer Original Research Open access 19 October 2023 Pages: 1669 - 1681
Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1) Hideto KamedaKohei HagimoriHiroaki Dobashi Original Research Open access 19 October 2023 Pages: 1683 - 1703
Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry Satoshi KuboYusuke MiyazakiYoshiya Tanaka Original Research Open access 19 October 2023 Pages: 1705 - 1723
Pregnancy Outcomes in Patients with Primary Sjögren’s Syndrome Undergoing Assisted Reproductive Therapy: A Multi-center Retrospective Study Minxi LaoGuangxi LuoDongying Chen Original Research Open access 24 October 2023 Pages: 1725 - 1739
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study Mark S. FinemanTimothy E. McAlindonYusuf Yazici Original Research Open access 30 October 2023 Pages: 1741 - 1752
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study Anisha B. DuaKerri FordAlan Kivitz Original Research Open access 31 October 2023 Pages: 1753 - 1768
Serum Calprotectin as a Potential Predictor of Microvascular Manifestations in Patients with Antiphospholipid Syndrome Yuan ZhaoWanting QiJiuliang Zhao Original Research Open access 31 October 2023 Pages: 1769 - 1783
Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis Silvia ScriffignanoFabio Massimo PerrottaEnnio Lubrano Brief Report Open access 16 September 2023 Pages: 1785 - 1794
Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial Cory PeruginoEmma L. CulverJohn H. Stone Study Protocol Open access 04 October 2023 Pages: 1795 - 1808
Correction: Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes Eugen FeistXenofon BaraliakosPeter-Andreas Löschmann Correction Open access 05 September 2023 Pages: 1809 - 1810
